LGMD2B/R2 Research Agent - Hardin AI Solutions

🤖 What the Agent is Doing

The AI agent searches PubMed, ClinicalTrials.gov, bioRxiv and monitors Sarepta Therapeutics every 12 hours for new announcements on SRP-6004 and LGMD2B/R2.

Every paper is read and analysed by GPT-4. The agent builds a growing knowledge base, generates treatment hypotheses for scientists, and calculates a Cure Progress Score based on all available evidence.

💡 Latest Treatment Idea

Loading...

📄 Most Recent Research

Loading...

🎯 Cure Progress Score

Calculated by AI from all collected research

Loading score...

All Research Papers

Loading...

Treatment Hypotheses

Generated by AI from all collected research. Updated every 24 hours.

Loading...

💊 Sarepta Therapeutics Watch

Monitoring Sarepta's website every 12 hours for new announcements about SRP-6004 (LGMD2B drug) and the NAVIGENE trial.

What We're Watching

DRUG

SRP-6004

Sarepta's LGMD2B gene therapy

TRIAL

NAVIGENE

Phase 1 proof-of-concept study

PIPELINE PAGE

sarepta.com

View Live →

PRESS RELEASES

Investor Relations

View Live →

Detected Updates

No updates detected yet. Agent checks every 12 hours.

➕ Add Article or Research

Paste any article, paper, or idea. The agent will learn from it and include it in future hypothesis generation.

Title / Source

📚 Team Contributions

No contributions yet.

What is LGMD2B / R2?

LGMD2B (also called LGMD R2 or Dysferlinopathy) is a rare, progressive genetic muscle disease. The muscles slowly weaken and waste away, primarily affecting the hips, shoulders, and upper arms. There is currently no cure and no approved treatment.

The Root Cause — The DYSF Gene

Caused by mutations in the DYSF gene on chromosome 2. This gene makes dysferlin — a protein that repairs tiny tears in muscle cell membranes. Without it, muscle cells slowly die.

Who Does It Affect?

Usually starts between ages 15–30
Both males and females equally
Inherited from both parents (autosomal recessive)
Progressive — most patients need a wheelchair within 10–20 years
Does not affect heart, breathing, or intelligence

Treatment Approaches Being Researched

Gene Therapy (AAV / Dual AAV) — deliver a working DYSF gene into muscle cells
Exon Skipping — skip the broken part of the gene
Protein Replacement — deliver functional dysferlin directly
Stem Cell Therapy — replace damaged muscle cells
SRP-6004 (Sarepta) — leading gene therapy drug in Phase 1 trial (NAVIGENE)

Our Mission

Hardin AI Solutions built this 24/7 AI agent to monitor all global research on LGMD2B/R2, analyse findings, and generate actionable treatment hypotheses — accelerating the path to a cure.